Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BMS-986507, Iza-bren, BL-B01D1
Izalontamab brengitecan · 5 trials · 5 indications
Phase 2
Phase 3
Assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR)
Assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by blinded independent central review (BICR)
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | - |
| Arm B | ACTIVE_COMPARATOR | - |
| Arm C | ACTIVE_COMPARATOR | - |
| Arm D | EXPERIMENTAL | - |
| Arm E | ACTIVE_COMPARATOR | - |
| Arm A1 | EXPERIMENTAL | - |
| Arm A2 | EXPERIMENTAL | - |
| Group A | EXPERIMENTAL | - |
| Group B | EXPERIMENTAL | - |
| Group C | EXPERIMENTAL | - |
| Group D | EXPERIMENTAL | - |
| Group E | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Iza-bren | DRUG | Specified dose on specified days |
| Osimertinib | DRUG | Specified dose on days |
| Pemetrexed | DRUG | Specified dose on specified days |
| Carboplatin | DRUG | Specified dose on specified days |
| Cisplatin | DRUG | Specified dose on specified days |
| Gemcitabine | DRUG | Specified dose on specified days |
| Nab-paclitaxel | DRUG | Specified dose on specified days |
| Paclitaxel | DRUG | Specified dose on specified days |
| Capecitabine | DRUG | Specified dose on specified days |
| BMS-986507 | DRUG | Specified dose on specified days |
| Pembrolizumab | DRUG | Specified dose on specified days |
| Nivolumab | DRUG | Specified dose on specified days |
| Pumitamig | DRUG | Specified dose on specified days |
Inclusion Criteria: * Participants must have histologically or cytologically confirmed non-squamous NSCLC, newly diagnosed locally advanced (Stage IIIB/IIIC), metastatic (Stage IVA/IVB), or recurrent disease not amenable to curative surgery or definitive radiotherapy and requiring systemic treatmen...
Top 20 of 75 competitors
Izalontamab brengitecan is an investigational therapy being studied in adults with advanced solid tumors, including lung cancer and breast cancer. It is not yet approved for any indication and remains in clinical development. Bristol-Myers Squibb is evaluating it both as a single agent and in combinations.
Izalontamab brengitecan is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company is the sponsor of the clinical program evaluating the agent in advanced solid tumors.
Izalontamab brengitecan is in Phase 1 clinical development. The only registered trial of the agent is a Phase 1 study that is currently recruiting participants. It has not completed any trials and is not approved by the FDA for any use.
Izalontamab brengitecan is being studied in the Phase 1 trial NCT06618287, titled a study to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors. The trial is recruiting and plans to enroll 416 participants across the United States, Australia, Canada, Chile, France, Italy, the Netherlands, Spain, Taiwan, and the United Kingdom.
Yes, izalontamab brengitecan is also known as BMS-986507. BMS-986507 is the Bristol-Myers Squibb development code for the same investigational agent. Both names refer to the identical molecule being studied in the Phase 1 trial NCT06618287 in advanced solid tumors.
Izalontamab brengitecan is being evaluated in a Phase 1 trial that includes patients with lung cancer among other advanced solid tumors. The study is testing the agent in combinations and includes biomarker-selected participants. It is investigational and has not been approved for lung cancer or any other indication.